Skip to content
Clinical Trials – home

Algemeen Stedelijk Ziekenhuis Campus Aalst

Verified siteinfo

Belgium Moorselbaan 164, 9300 Aalst, Belgium

  • 3 trials recruiting
  • Atrial fibrillation · Bladder cancer · Obesity
  • Adult patients

About Specializations

Algemeen Stedelijk Ziekenhuis Campus Aalst in Aalst, Belgium specialises in clinical trials of conditions such as Atrial fibrillation, Bladder cancer, Obesity, Acute coronary syndrome, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Algemeen Stedelijk Ziekenhuis Campus Aalst, clinical research in cardiovascular diseases focuses on reducing the burden of coronary artery disease, non-obstructive coronary artery disease, and atrial fibrillation-related stroke risk. These studies are designed to test new treatment strategies and improve prevention for people at elevated heart risk.

  • Evaluating lipid-lowering therapies for people at high risk of heart attack and stroke
  • Studying approaches to slow or reduce coronary plaque progression in coronary artery disease
  • Assessing anticoagulation strategies to lower embolic events after atrial fibrillation treatment

This area of research aims to improve long-term cardiovascular protection and help identify better ways to prevent serious events before they occur.

Musculoskeletal Diseases

Research in musculoskeletal diseases at this hospital includes peripheral spondyloarthritis, with a focus on finding more effective ways to bring inflammation under control and support remission. The work compares established treatment pathways with newer biologic-based approaches.

  • Investigating treatment strategies for inflammatory joint disease
  • Comparing conventional therapies with early biologic intervention
  • Exploring options to improve symptom control and remission rates

The goal is to refine care for people with chronic inflammatory rheumatic conditions and improve outcomes through more targeted treatment choices.

Nutritional and Metabolic Diseases

Clinical trials in nutritional and metabolic diseases address obesity and type 2 diabetes, with a strong emphasis on weight management and metabolic health. These studies are testing whether new therapies can support weight loss and improve control of diabetes alongside lifestyle changes.

  • Evaluating treatments for overweight and obesity in people with diabetes
  • Studying therapies that may help improve weight and blood sugar control
  • Supporting better cardiometabolic risk reduction through new treatment options

This research reflects growing interest in therapies that may help patients manage both excess weight and diabetes more effectively.

Virus Diseases

The virus diseases portfolio at Algemeen Stedelijk Ziekenhuis Campus Aalst includes studies in chronic hepatitis B infection. The research is focused on understanding treatment interruption and viral outcomes, with the broader aim of improving long-term management of this persistent infection.

  • Examining outcomes after stopping antiviral treatment in chronic hepatitis B
  • Investigating factors that may influence viral control over time
  • Supporting better strategies for managing long-term hepatitis B care

This work is intended to help clarify which patients may benefit from different treatment approaches and to inform safer, more personalized care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Moorselbaan 1649300 AalstBelgium
Recruiting now
3 trials
Conditions studied
18
Partner status
Verified site

More sites in AalstBelgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

14 clinical trials

Study on Colchicine for Patients with Coronary Artery Disease After Percutaneous Coronary Intervention

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Az St-Jan Brugge-Oostende A.V.

Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:St Antonius Hospital

Study on Edoxaban for Patients with Atrial Fibrillation and Coronary Syndrome Undergoing PCI

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:St Antonius Hospital

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Chronic hepatitis B

Not recruiting

Study on Stopping Tenofovir Alafenamide, Tenofovir Disoproxil, and Entecavir in Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Entecavir
  • Sponsor:Antwerp University Hospital

Study on Peripheral Spondyloarthritis: Comparing Methotrexate Disodium and Golimumab for Early Remission in Adult Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Universitair Ziekenhuis Gent

Atrial fibrillation+2

Not recruiting

Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Ottawa Heart Institute

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.